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The fast-advancing progress in the research of nanomedicine and microneedle applications in the past two
decades has suggested that the combination of the two concepts could help to overcome some of the
challenges we are facing in healthcare. They include poor patient compliance with medication and the
lack of appropriate administration forms that enable the optimal dose to reach the target site.
Nanoparticles as drug vesicles can protect their cargo and deliver it to the target site, while evading the
body's defence mechanisms. Unfortunately, despite intense research on nanomedicine in the past 20
years, we still haven't answered some crucial questions, e.g. about their colloidal stability in solution and
their optimal formulation, which makes the translation of this exciting technology from the lab bench to
a viable product difficult. Dissolvable microneedles could be an effective way to maintain and stabilise
nano-sized formulations, whilst enhancing the ability of nanoparticles to penetrate the stratum corneum
barrier. Both concepts have been individually investigated fairly well and many analytical techniques for
tracking the fate of nanomaterials with their precious cargo, both in vitro and in vivo, have been
established. Yet, to the best of our knowledge, a comprehensive overview of the analytical tools
encompassing the concepts of microneedles and nanoparticles with specific and successful examples is
missing. In this review, we have attempted to briefly analyse the challenges associated with
nanomedicine itself, but crucially we provide an easy-to-navigate scheme of methods, suitable for
characterisation and imaging the physico-chemical properties of the material matrix.Introduction
Invisible to the naked eye, nano-sized drug delivery systems
(DDSs) showed promise in revolutionizing the treatments of
many conditions and diseases that were considered effectively
untreatable. They showed great potential in improving the
efficacy of existing drugs and conventional therapy. New
generations of nanomedicines such a dendrimers, liposomes,
synthetic and bio-inspired nanoparticles (NPs), nanoclusters,
nanorods and nanoplates1–6 have been introduced as drug
carriers, due to their small size and high volume-to-surface
ratios, aiming to evade the body's natural defence mecha-
nisms. However, the reality is that the translation of promising
NPs from the benchtop to the marketplace is extremely chal-
lenging and has led to a drive to better understand bio–nano
interactions and to develop strategic frameworks that canof Greenwich and Kent, Anson Building,
-mail: res91@kent.ac.uk
ex University, The Burroughs, Hendon,
Kent, Ingram Building, Canterbury, Kent
Italiano di Tecnologia, Via Morego 30,
–3347efficiently test potential toxicological effects induced by NP
exposure.
One area that has been highly studied has been the inter-
action of NPs with complex biological uids (e.g. blood and
serum) and the formation of biomolecular coatings on particle
surfaces that can govern the NP's biological fate. This surface
fouling is attributed to the adsorption of biomolecules (mainly
protein) around NP surfaces and is referred to as the ‘protein
corona’. The corona is composed of two layers: ‘hard’ and ‘so’.7
A hard corona is a near-monolayer of tightly bound biomole-
cules to the NP surface (though not irreversibly bound). The
‘so’ corona surrounds this hard corona layer and is composed
of rapidly exchanging and more loosely associated biomole-
cules. The hard corona on the NP surface is believed to be the
layer that interacts with cells8,9 and, consequently, has begun to
be regarded as dening the ‘bio–nano interface’ that can result
in unpredicted biological interactions10,11 Considering the
continuously growing popularity of NPs in bioapplications12–14
like nanomedicine, there has been increasing importance
placed on assessing NP interactions with complex biological
uids. For example, Tenzer et al.15 showed that a corona can
form in 30 seconds on silica NPs. This poses a challenge to
nanomedical applications as NP surfaces are oen engineered
to recognise specic receptors on cell surfaces to impart particleThis journal is © The Royal Society of Chemistry 2021































































































View Article Onlinetargeting. For example, it has been shown that corona forma-
tion on biomolecule-functionalised NPs can lead to a loss of
targeting capabilities16,17 or can even contribute to particle
biodistribution.18 However, as the understanding of corona
formation increases, there have been reports on the manipu-
lation of the hard corona composition to modulate biomolec-
ular19 and cellular interactions.20
With the wealth of research on the corona over the past
decade it is evident that a variety of factors play a role in its
formation (temperature of incubation, time of incubation, and
the total mass of biomolecules in the exposure media) and also
the analytical methods used for its characterization.21 A 2019
article by Lynch and co-workers highlighted such character-
isation challenges and suggested the best practices for experi-
mental design for studying corona–nanomaterial interactions
and the subsequent reporting of results.22 Several regulatory
bodies have also highlighted the relevance of the corona,
including the US Food and Safety Authority23 and the European
Food and Safety Authority,24 and have reported the importance
of evaluating the toxicological impact of nanomaterials due to
the acquisition of new, corona-derived biological identities.25
Nonetheless, regulatory gaps and standardised approaches to
the characterisation of the biomolecular corona remain in
nanomedicine despite the acceptance of its importance.
The emergence of the importance of the biomolecular
corona is indicative of the fact that the use of nanomaterials in
biological applications continues to present new challenges and
considerations for nanomedicine. The standardisation and
identication of knowledge gaps that could accelerate the
translation of nanomedicines into useable therapies is there-
fore required. However, a lack of robust datasets and regulatory
experience with innovative nanomaterials means that knowl-
edge gaps to achieve this goal exist.
Halamoda-Kenzaoui et al.26 attempted to tackle this problem
by conducting a gap analysis based on information released by
regulatory scientists and made four observations where stand-
ardisation is required in nanomedicine:
(1) Methods for assessing.
 drug loading/release from nanomaterials.
 protein corona formation.
 interactions of nanomaterials with the immune system.
 nanomaterial accumulation in biological tissues.
(2) Guidance for assessing the comparability of methods
used to evaluate nanomedically relevant endpoints.
(3) Reference materials relevant to nanomedicine.
(4) Identication and subsequent recognition of standards
developed in other sectors.
It is also important to consider safe-by-design (SbD) as
a useful tool for assessing the potential hazards associated with
a given nanomedicine. The purpose of SbD is to assess the
safety of a nano-enabled product as early as possible in the
innovation process, the aim of which is to reduce side effects on
human health and environmental impacts through alterations
in nanomaterial designs. This encourages safety throughout the
lifecycle of a nanomaterial for a given intended use. SbD
therefore differs from conventional risk assessment processesThis journal is © The Royal Society of Chemistry 2021that typically only consider safety once a product is fully
developed.27
‘Grouping’ is one approach to streamline the identication
of potential hazardous side effects associated with newly
developed nanomaterials, i.e. utilising similar physicochemical
characteristics and associated hazard endpoints to establish
potential risk to health (or the environment). For example,
a structure–toxicity paradigm has identied long, biopersistent,
brous nanomaterials as hazardous upon pulmonary expo-
sure.28 It can therefore be hypothesised that newly developed
nanomaterials with a ‘high aspect ratio’ (i.e. physicochemical
characteristic: shape) may be ‘grouped’ as potentially toxic/
carcinogenic in pulmonary exposure scenarios. Such hypoth-
eses can then be tested using structured approaches based on
standardised physicochemical and toxicological methods.29,30
These approaches can be useful to establish the potential
hazards of nanomedicines early in the innovation process.
However, general SbD strategies are typically stage-gate based
and, according to Schmutz et al.,31 are not reective of the ‘drug
discovery and development’ eld of nanomedicine and through
the GoBioNanoMat consortium, SbD methodical approaches
were adapted to nanomedicine applications (Fig. 1). Unlike
general SbD approaches, the nanomedicine SbD approach uses
iterations (Fig. 1, red arrows), whereby knowledge can be built to
better understand the physicochemical properties and biological
impacts of developed nanomedicines. The nanomedicine SbD
approach also incorporates key manufacturing considerations
like batch-to-batch uniformity testing, stability monitoring and
adherence regulatory requirements. However, the nanomedicine
approach only sets out guidelines to develop safe nanomedicines
and does not present guidance for evaluating the efficacy of the
therapies. Nonetheless, such nanomedicine-specic develop-
ments are what is required to ensure that the undoubted poten-
tial of nanomaterials in medicine can be realised and pushes the
eld in an important direction by establishing framework stake-
holders (innovators, manufacturers, and regulators) required to
successfully translate nanomedicines into useable, cost effective
therapies. These considerations should be to the forefront of any
microneedle-based nanomedical application.
The advantages of using engineered nanomaterials for
medicinal purposes have been discussed extensively in many
comprehensive reviews.32–40 However, despite the massive
interest in nanomedicine, effectively all the developed concepts
or commercially available products have been formulated as
solutions and suspensions, aimed to be injected into the
systemic circulation. Unfortunately, that brings about one major
challenge that has not been fully addressed yet – nanomaterials
have a tendency to aggregate/agglomerate in solution.41 Aggre-
gation is observed when dispersed molecules collide to form
aggregates,42 which are ‘an assembly of particles exhibiting an
identiable collective behaviour’,43 and the rate depends on the
frequency of collisions and the probability of cohesion.44,45
Although agglomeration is similar in that it is dened as
a process in which dispersed particles assemble46 by growing
together or partial fusion,47 it refers to stronger bonds forming
between the agglomerates.43 The aggregation/agglomeration
phenomena, illustrated in Fig. 2,48 pose signicant challengesAnal. Methods, 2021, 13, 3326–3347 | 3327
Fig. 1 The safe-by-design approach for the development of nanomaterials for medical applications. Blue arrows refer to the flow of bio–
nanomaterials from design to storage to transport. Red arrows allow for feedback/redesign whenever the bio–nanomaterial is unsafe or inef-
ficient.28 (M. Schmutz, O. Borges, S. Jesus, G. Borchard, G. Perale, M. Zinn, Ä. A. J. A. M. Sips, L. G. Soeteman-Hernandez, P. Wick and C. Som,
Front. Bioeng. Biotechnol., 2020, 8, 1–7. Copyright (2003) National Academy of Sciences, U. S. A.)































































































View Article Onlinefor the translation of nanomedicine DDSs from the laboratory
bench to a clinical product. Pristine NPs, such as ZnO and TiO2,
have been topically applied on the skin for more than a decade,
mostly for cosmetic purposes. However, despite their inherently
small size, NPs cannot freely penetrate through the skin's
outermost layer, the stratum corneum, due to the size-exclusion
dependency of the skin.49 Fortunately, this is where the two
separate concepts, microneedles (MNs) and nanomaterials, can
be exploited together in order to convert the promise presented
more than 20 years ago into a reality.
One signicant milestone that offers a possibly elegant
solution to the MN–NP delivery hypothesis came in 2003, when
the Prausnitz research group50 were among the rst to fabricate
dissolvable microneedles (DMNs). Their pioneering work has
prompted scientists to ask many relevant research questions,
one of which is particularly interesting: could the formulation
of nanoparticles inside dissolvable microneedles nally solve
the aggregation/agglomeration problems?Many interesting and
comprehensive reviews giving praise51–55 but also critique56,57 to
the plethora of functional NP designs have been presented.
More recently, it has been established that NPs can be stabilised
and released from hydrogel-like materials, thus effectively pre-
venting aggregation.58,593328 | Anal. Methods, 2021, 13, 3326–3347In the rst part of this review, we will specically focus on
DMNs, fabricated from biodegradable matrices, which provides
a suitable environment for NPs, facilitating the delivery of NPs
through the skin into the body. Importantly though, in the
second part of the review we will provide a comprehensive
overview of the analytical tools associated with MNs and NPs,
with specic and successful examples. To the best of our
knowledge, as no one has done before, we have attempted to
provide an easy-to-navigate scheme of methods, capable of
analysing the size-dependent biological function of NPs and
their drug-targeting abilities and toxicological response.
Importantly, this review will provide a clear strategy of all the
analytical steps scientists need to consider in order to fabricate
new drug delivery systems that might shape the future of home
and community-based healthcare.Microneedles
The skin covers approximately 16% of the body and comprises
several layers of epithelial, mesenchymal, glandular and neu-
rovascular components, approximately 2 mm thick.60 Skin has
many functions but the most prominent is the protective
function from environmental stressors such as infectiousThis journal is © The Royal Society of Chemistry 2021
Fig. 2 Diagram showing the mechanism difference between aggregation (a) and agglomeration (b).48































































































View Article Onlineorganisms, pollution, radiation from the sun, etc. People have
been applying a wide variety of substances on their skin for
thousands of years, mostly for therapeutic and cosmetic
purposes. Since the official approval of the rst transdermal
system for systemic drug delivery in 1979 for the treatment of
motion sickness, several generations of transdermal drug
delivery products have been explored.61 The advances in
microfabrication in the mid-1990's enabled large scale research
exploration of a new technology for transdermal drug delivery –
microneedles.62 Researchers use the terminology microneedles
and microneedle arrays to refer to arrays of individual micro-
needles and oen refer to a single microneedle as a needle. For
this review, when the term microneedles (MNs) is used, this
refers to an array of individual microneedles, whereas micro-
needle (MN) refers to an individual needle. When theFig. 3 3D models of a nanoparticle with drug cargo (a) and a microneed
array through skin (c).
This journal is © The Royal Society of Chemistry 2021abbreviation DMNs is used, this refers specically to dissolvable
microneedle arrays.
A MN has been dened as ‘a canula which is either solid or
hollow with an approximate length ranging between 50 and 900
mm and an external diameter of 300 mm’.63 However, this is not
entirely accurate as someMNs are over 900 mm in length, i.e. for
cosmetological applications, and can have varying base diam-
eters. For example, Dermarollers® are very common, clinically
used MNs for cosmetic procedures and can range in needle
length from 0.5–3 mm.64–68 Depending on the length of the MN,
penetration into the dermis can be achieved (Fig. 3b), by-
passing the stratum corneum barrier of the skin, e.g. during
collagen induction procedures where the needle length is 1.5
mm.69 The stratum corneum prevents certain sized materials
from passing through, i.e. those over 2 nm in size or 500 daltonsle array (b) and a diagram showing the application of the microneedle
Anal. Methods, 2021, 13, 3326–3347 | 3329































































































View Article Onlinein molecular weight.70 Therefore, the delivery of pharmaceuti-
cals, whether in vesicles or not, is challenging without assis-
tance. The use of microneedles can overcome this size-
dependent barrier.49 For this reason, combining microneedle
and nanoparticle technologies is an attractive idea to improve
drug delivery and the administration of therapies. MNs were
actually patented for the rst time in 1976,71,72 where the
structure of an array was claimed to enable controlled drug
release from a reservoir through the stratum corneum, but it took
another 25 years for them to attract signicant interest. Many
variations of this transdermal delivery concept have since
appeared. As illustrated in Fig. 4b, the interest in this new drug
delivery technology is still exponentially growing – more than
1100 papers have been published on the topic of microneedlesFig. 4 (a) Timeline showing the years in which the first patents were filed
were found using the advanced search of the title and abstract with the
from 1970–2020; (b) publications of papers on nanoparticles and micro
“microneedles”were searched separately and the following document typ
short survey; undefined; for nanoparticles – note; short survey; letter;
before averaging the number of publications for five year periods.
3330 | Anal. Methods, 2021, 13, 3326–3347just in the past 10 years. Fabricated as low-cost patches, they are
simple for patients to apply73 and have been trialled to deliver
a wide range of substances, such as lowmolecular weight drugs,
protein drugs, cosmetics, biotherapeutics, and bio-
macromolecules, targeting vaccine delivery to antigen-
presenting cells in the skin.39,40,71,74–85
The potential of DMNs to be used as transdermal DDSs was
rst demonstrated when Park et al.50 synthesised the rst
biodegradable MNs. They fabricated DMNs from polyglycolide
(PGA), polylactide (PLA) and poly lactide-co-glycolide (PLGA)
and successfully encapsulated two model drugs into them –
calcein as a model for low molecular weight drugs and bovine
serum albumin (BSA) as a model for high molecular weightfor the main microneedle applications using Espacenet5 – the patents
keyword microneedle and then refining the dates to five year periods
needles since 1970 from Scopus – the keywords “nanoparticles” and
es were excluded: for microneedles – conference review; note; letter;
conference review; retracted; erratum; abstract report; undefined –
This journal is © The Royal Society of Chemistry 2021































































































View Article Onlinedrugs. They demonstrated the ability of DMNs to insert into
skin and release their cargo.
Early research into DMNs was mainly about perfecting their
shape, as the geometry and size of DMNs, as well as the matrix
materials used, play a vital role in how well they penetrate the
skin. In terms of geometry, spherical needle tips have been
shown to have a higher fraction force than square needle tips,
suggesting that they can withhold more stress.86 Loizidou et al.87
(Fig. 5)87,88 studied hexagonal, square and triangular DMNs and
predicted by simulations that the hexagonal DMNs would
withstand higher stress until buckling occurs. It was suggested
that the geometry and aspect ratio affect the mechanical prop-
erties of DMNs and the penetration depth. Although these
studies can help provide an insight into what shaped DMNs
would be best to use, this can also be affected by other
geometrical factors, such as the needle length, centre-to-centre
spacing and base diameters. The best shape can also be affected
by the material matrix used. A detailed analysis of the MN shape
is presented by Nava-Arzaluz et al.89 The analysis of DMNs is
carried out using a variety of techniques, ranging from simple
imaging techniques, such as light microscopy, to more
advanced techniques, such as optical coherence tomography
(OCT). The aim of this review is to provide an outline of the data
each technique can produce and how it is benecial. The aim is
to guide researchers in the decision of what techniques work
best for their specic DMNs.
One of the main potential and earliest applications for
DMNs is a new way to administer vaccinations, such as inu-
enza,90–95 measles,96 polio,97 hepatitis B (HBV)98 and tetanus
toxoid99 vaccines. One of the most recent studies into using
DMNs as a way to administer vaccinations is for COVID-19,
which is an ongoing pandemic. Kim et al.100 have shown the
potential use of a recombinant spike (S) protein as the vaccine.
They have also demonstrated the benets of DMN delivery over
subcutaneous delivery. First, they developed three types of
MERS-S1 vaccines from the native coronavirus structure, whichFig. 5 SEM images of different shapes of microneedles most frequently
pyramid; hexagonal-based pyramid (adapted from Loizidou et al.87 and M
This journal is © The Royal Society of Chemistry 2021all showed strong reactivity and antibody production. These
vaccines were then formulated into DMN arrays of 10  10
obelisk-shaped needles of height 750 mm and base diameter 225
mm. The matrix used to fabricate these arrays was carbox-
ymethyl cellulose (CMC) by a spin-drying technique, i.e.
centrifugation. In vivo studies were carried out to compare the
antibody response of the different types of vaccines and deter-
mine whether the delivery route effected the response. In terms
of an immediate antibody response, for subcutaneous injection,
only the vaccine with an adjuvant showed an antibody response,
whereas for DMNs, an antibody response was seen regardless of
whether an adjuvant was present or not, and it was a signi-
cantly higher response than that for subcutaneous injection.
They observed that the subcutaneously injected vaccines did
not appear to produce an antibody response until two weeks
aer a booster injection, and even when a response occurred, it
was signicantly lower than that seen for vaccines administered
by DMNs. A long-term immune response was observed in 23
and 55 weeks for both subcutaneously injected and DMN
injected vaccines. Subcutaneous injection showed the same or
increased antibody levels as in week 6; however DMNs showed
signicantly higher levels, suggesting the potential for long-
term immune responses by DMN vaccination. The steri-
lisation of the vaccine did not appear to affect it. Although it can
be concluded that these vaccines, whether in combination with
DMN delivery or adjuvant and subcutaneous delivery, have
great potential as COVID vaccines, especially now that this
particular strain has been sequenced. However, it is too early to
predict whether humans will have the same responses.
Other potential applications of DMNs for medical purposes,
include intraocular delivery,101 diagnostic tools,102 delivery of
certain medications103,104 and cancer therapy.105 One of the most
interesting studies was the development of an effervescent
patch for long-term contraception using levonorgestrel (LNG).
Recently, DMNs consisting of PLGA and diglyme/water (95 : 5)
needles with LNG encapsulated attached to a backing plate ofused – conical; beveled tip; triangular-based pyramid; square-based
cAllister et al.88).
Anal. Methods, 2021, 13, 3326–3347 | 3331































































































View Article Onlinepolyvinylpyrrolidone (PVP) were studied.106 When the patch is
inserted into the skin, the interstitial uid penetrates the patch
and begins to dissolve the backing plate. Sodium bicarbonate
and citric acid from within the backing plate react to give off
effervescence, causing the connection between the backing
plate and needles to become weakened and break. This all
occurs in a span of 10 seconds. The backing plate can then be
removed, leaving the needles to slowly dissolve over time giving
a sustained release of LNG. The DMNs were 10  10 arrays of
conical shaped needles with a height of 600 mm, base diameter
of 150 mm and tip diameter of 10 mm. The LNG release prole
was rst studied in phosphate buffered saline (PBS) showing
a sustained release of LNG for over one month. This was
repeated in vivo using rats and displayed the same ndings. The
ability of these DMNs to insert and produce effervescence in
humans was conrmed using DMNs without the LNG encap-
sulated and water-soluble needles in women of reproductive
age. It was concluded that these DMNs provide a rapid, efficient
way of administering contraception that releases the hormones
and maintains the required plasma concentration for over one
month.
MNs have been used to enhance the permeation of NP drug
vesicles (Fig. 6) for over a decade now, as discussed in previous
reviews,39,89 and these were rst done using solid MNs followed
by topical application, hollow MNs delivering NP solutions and
coated MNs. Drug delivery using DMNs was widely studied by
encapsulating the drug directly into the DMN matrix; however
protecting these drug molecules in NPs before encapsulation
into DMNs was not demonstrated until around the 2010s.
Ovalbumin (OVA), as a model antigen, was encapsulated into
PLGA-NPs and delivered using Gantrez DMNs to observe anti-
tumour and antiviral immune responses.107 The DMNs con-
sisted of 19  19 needles of 600 mm height. In vivo studies of
mice skin using OCT showed successful insertion of DMNs
without mechanical failure and rapid dissolving of DMNs to
release their cargo. However, when trying to determine whetherFig. 6 Schematic showing the process of microneedle application
and dissolution of needles into skin – (a) schematic of how nano-
particles aggregate and agglomerate over time in solution with
eventual sedimentation; (b) diagram of how dissolvable microneedles
stabilise and then release nanoparticles from their matrix.
3332 | Anal. Methods, 2021, 13, 3326–3347dendritic cells were capable of taking up PLGA-NPs, it was seen
that the majority of the NPs released from the DMNs localised
to the insertion site. As the OVA-NPs were smaller than 100 nm
in size, they were signicantly less likely to be spontaneously
removed from the body. Not only did the encapsulation of OVA
into NPs promote sustained delivery, it also increased their
stability in DMNs compared to antigens. In vivo studies showed
that one dose of OVA by DMNs produced tumour killing cells,
suggesting that this delivery method may be effective for
immunotherapy strategies, especially as it induced immunity
against a viral challenge using a recombinant Sendai virus.
Later studies by this group supported these ndings and
demonstrated that DMN vaccination can lead to memory
responses.108
Wound healing and possible infection are the major
concerns in the medical eld. Xu et al.109 investigated the ability
of DMNs to enhance the drug delivery of antimicrobials. Some
antimicrobials (chloramphenicol (CAM) specically) can cause
anaemia as they heighten cytotoxicity. In the above study, CAM
was therefore incorporated into gelatin NPs, to reduce this
cytotoxic effect. The NPs were characterised by dynamic light
scattering (DLS) and transmission electron microscopy (TEM),
showing their size to be 197.6 nm and 131.6 nm respectively.
DLS also showed a zeta potential of 12.6 mV, which is above
the literature value of good stability at charges more negative
than 30 mV, suggesting NP instability.41 The encapsulation
and loading efficiencies of the NPs, as well as their release, were
studied using high-performance liquid chromatography
(HPLC). It was observed that CAM was released by gelatinase in
a controlled manner. To test the cytotoxicity of the NPs, free
CAM, plain NPs and CAM-NPs were incubated with broblast
cells and CCK-8 assays were run. They showed reduced cyto-
toxicity of the CAM-NPs in comparison to free CAM. Once these
NPs had been fully characterised, they were encapsulated into
arrays made from PVP. The DMNs were imaged by scanning
electron microscopy (SEM) and uorescence microscopy,
showing that the CAM-NPs were distributed in the tips. When
the DMNs were inserted into the biolms, their structure was
disrupted allowing the dye (used as amodel drug) to diffuse into
the biolm matrix. It was concluded that these DMN arrays
containing CAM-NPs allowed for local and specic drug release
within biolms, suggesting the potential of DMNs for the
treatment of bacterial biolms in wounds.
MNs, although a relatively novel research concept, have
gained great interest due to their potential for transdermal drug
delivery, with over 54 clinical trials currently being evaluated.110
However, there are still challenges to overcome before their
translation to clinical use. One of the main challenges is the
dosage and activation of immune cells beneath the skin to
benet the diffusion of the cargo.110 If the required dose needs
to be on a larger scale, then the size of the MNs will need to be
adjusted. This may lead to continuous re-application of MNs to
achieve the desired dosage. This can bring about its own chal-
lenges, in terms of affecting the characteristics (Table 1)111,112 of
the MNs, as well as safety concerns.
Another potentially signicant challenge of MNs is their
manufacturability.110 Although MNs for cosmetic applicationsThis journal is © The Royal Society of Chemistry 2021
Table 1 Summary of the characteristics, applications, and challenges of biodegradable microneedles
Characteristics Applications Challenges
 Fracture force – ability to resist insertion force  Vaccination  Dosage – repeatability
 Penetration depth – required depth of tissue
for desired application
 Biopharmaceutical's delivery – proteins;
nucleic acids; cells; tissues
 Size of the patch – higher the dose,
larger the patch
 Dimensions – length 1–900 mm; base width
50–300 mm; tip diameter 1–50 mm
 Drug delivery – pharmaceuticals;
insulin; birth control; cancer therapy
 Variability in skin – skin layer
thickness; skin hydration; skin age
 Margin of
safety ¼ force required for insertion
force at which MNs break
 Diagnostics – sensing; sample
collection
 Manufacturability – how to fabricate
on a large scale with pharmaceuticals
encapsulated
 Effect of the length on pain – as the length
increases, pain increases
 Cosmetics – wrinkle treatments;
acupuncture; acne treatment;
scar treatment
 Patient compliance – educating patients;
monitoring of patients
 Transepidermal water loss – evaluation of skin
before and aer MN application
 Biocompatibility – most made from
sugars but are these biocompatible on this
larger scale; cytotoxicity studies Biological safety testing – cytotoxicity studies































































































View Article Onlinehave already been successfully manufactured, e.g.
Dermarollers®, manufacturing patches that contain therapeu-
tics could be difficult due to the muchmore stringent regulatoryFig. 7 Flowchart of the analytical techniques that can be used for the ch
microneedles.
This journal is © The Royal Society of Chemistry 2021and quality control requirements. For example, can the drug
possibly cause structural and mechanical defects in the arrays?
This also raises additional questions of safety of MNs – willaracterisation, imaging and drug release and activity of nanoparticles in
Anal. Methods, 2021, 13, 3326–3347 | 3333































































































View Article Onlinethere be long-term damage to skin from repetitive application?
Is the distribution of cargo from MNs accurate?
The desire of microneedles is the ability to improve patient
compliance and assist in at-home applications. However, there
are several challenges to be addressed. The patient may need to
be educated in how to correctly apply microneedles, to ensure
that a clinically relevant dose has been delivered. If the patient
needs to apply more than one patch, medical staff or even
insurers may need to monitor this, by use of sensors within the
patches, or by contacting the patient on a regular basis.
Although the benet of MNs for transdermal delivery of thera-
peutics is clear and understandable, potential can only be
realised aer very careful evaluation of each step as this exciting
technology makes its way from laboratory benches to the clinic.
For further discussion of the characteristics, applications and
prospects of microneedles, the reader is directed to various
reviews on these topics.110–114
As shown by the current research into DMNs, they have great
potential as transdermal drug delivery systems for nano-
medicines. However, for their use in the medical eld, there
needs to be robust evidence of how to carry out their analysis.
Currently there are over 25 techniques that can be used for the
analysis of DMNs alone or with nanomedicines encapsulated,
varying from common techniques that can be performed in
almost any laboratory, to those that are specialised and found at
specic labs only. To the best of our knowledge, there is no
literature reviews on the analysis of DMNs or NPs encapsulated
into DMNs. Therefore, we have created a owchart (Fig. 7) fol-
lowed by a detailed description of each technique to allow the
interested reader to determine what techniques are most suit-
able to analyse particular DMNs.Analytical techniques
Denitions
 Characterisation – this refers to the shape and size of the
arrays as well as the penetration depth and fracture force of the
needles.
 Non-destructive – this refers to when a sample can be
recovered without physical or chemical change aer analysis.
 Destructive – this refers to when a sample cannot be
recovered without physical or chemical change aer being
analysed, either due to the technique being destructive, or if
doping or coating of the sample is required to be visible for
particular techniques.
 Coating – this refers to when an array, particularly the
needles, is coated with a chemical, such as gold, to be visible for
particular techniques.
 Doping – this refers to chemically bonding a dye or other
chemical to the nanoparticles or array matrix in order to be
visible for particular techniques.Characterisation
Raman spectroscopy. Raman spectroscopy involves illumi-
nating a sample with a high intensity laser causing scattering.
Some of this scattering is of the same wavelength as the light3334 | Anal. Methods, 2021, 13, 3326–3347source (Rayleigh scattering); however a small amount is scat-
tered at a different wavelength (Raman scattering) depending
on the molecules' chemical structure.115 The distribution of
graphene oxide (GO) in the DMNmatrix of PVP was investigated
using Raman spectroscopy.116 The diode laser excited the
sample at 532 nm and a 1 mm area was viewed. The spectrum
showed the uniform distribution of GO throughout the polymer
matrix.
Differential scanning calorimetry (DSC). DSC looks at how
a material's heat capacity changes with temperature. A known
mass sample is heated or cooled and changes in heat capacity
are tracked as heat ow changes.117 This is usually done in
comparison to a reference, with both the reference and sample
held at the same temperature. The difference in the amount of
heat required to increase in the temperature of the sample and
reference is measured as a function of temperature and may be
endothermic or exothermic.118
DMNs made from sugar glass can be characterised using
DSC. Martin et al.119 created sugar glass lms and analysed
them by DSC, where the sugar glass lms were heated between
20 and 220 C, at increments of 10 Cmin1. The DSC spectrum
showed peaks at 101 and 214 C as well as an endothermic
region between 130 and 150 C for the trehalose anhydrous
(TRA) lm. The DSC spectrum of unprocessed TRA was
compared to the TRA lm spectrum and showed only a single
peak at 200 C when the trehalose crystal melted. The trehalose
dihydrate (TRD) lm also showed similar peaks to the TRA lm,
indicating that both TRD and TRA solutions form similar sugar
glass. For the sucrose (SUC) lm, a peak was observed at 191 C
when the SUC crystal melted. The combination of both TRA and
TRD with SUC was then studied by DSC, both at 75 : 25% w/w%
of TRA–SUC and TRD–SUC. Both showed similar spectra with
a peak at 97 C and a poorly dened endothermic region at 130–
170 C. This further supported the conclusion that TRA and
TRD once dehydrated form sugar glass of a similar nature.
DSC can also be used to determine the glass transition
temperature (Tg) of DMNs which can determine their stability
and moisture content over time, for example by increasing the
temperature to 200 C in 10 Cmin1 increments and observing
the Tg of fresh DMNs in comparison to that of stored DMNs.120
When disruptions start to occur in the heat ow versus
temperature curve, then this represents the Tg. Kolluru et al.120
found that over storage time, the Tg of DMNs increased from
48 C to 59 C, suggesting that the residual moisture content
decreases over time. The stability of the DMNs appeared to be
better at lower temperatures of 5 C and 25 C in comparison to
that at 40 C, which may be due to this higher temperature
being closer to the Tg.
Thermogravimetric analysis (TGA). In TGA, the mass of
a substance is monitored as a function of temperature. A
precision balance monitors the weight of the sample inside the
furnace as the temperature increases or decreases in a linear
way with time.121,122 TGA can give information of a sample's
thermal stability and the fraction of volatile components
present,123 which allow for the characterisation of DMNs. Tha-
kur et al.101 heated their samples to 150 C at a heating rate of
10 C min1 and determined the moisture content at 110 C byThis journal is © The Royal Society of Chemistry 2021































































































View Article Onlinecalculating the percentage reduction in mass. Martin et al.119
carried out a similar study by increasing the temperature from
20–220 C at a rate of 10 C min1 to observe the change in the
mass of their DMN matrices.
Kolluru et al.120 used TGA to determine the residual moisture
content of their DMNs fabricated from 35% w/v% sh gelatin
and 10% w/v% D-sorbitol. These arrays consisted of 10  10
needles with a height of 650 mm. TGA was used to analyse DMNs
and study the effect lyophilisation and drying temperature had
on the residual moisture content of the arrays. They observed
that the residual moisture content depended on the drying
temperature and sometimes lyophilisation. Aer storage for
one week at 40 C an equilibrium state was seen. At 5 C, the
residual water content was highest in comparison to drying at
25 C and 40 C. However, lyophilisation reduced this moisture
content for air drying at 5 C but not for any other temperatures.
It was concluded that as the storage temperature increased, the
DMN moisture content decreased due to the matrix becoming
more amorphous.
Fluorescence spectrometry. In uorescence spectrometry,
the sample is illuminated with a single excitation wavelength,
causing light to be emitted from the sample. This emitted light
is measured, usually at a 90 angle to avoid measuring any
excited light that is transmitted through the sample and is
processed to form a uorescence spectrum that can be used to
identify the sample.
As Bhatnagar et al.105 demonstrated, uorescence spec-
trometry can be used to determine concentrations, specically
of drug cargo (doxorubicin (DOX) and docetaxel (DTX)) in DMNs
fabricated from PVP and polyvinyl acetate (PVA). A calibration
curve was plotted for known concentrations of DOX and then
drug released from dissolved DMNs was determined. The
concentration of DOX loaded into the DMNs was measured
using an excitation wavelength of 475 nm and emission wave-
length of 595 nm and showed a drug loadingmass of 621.8 mg in
DOX-MNs and 533.5 mg in DOX–DTX-MNs. Fluorescence spec-
trometry was then used to study the DMN dissolution and
produce release proles. It was seen that DOX was completely
released from DOX–DTX-MNs within ve minutes aer appli-
cation and 15 minutes for DOX-MNs. Ex vivo skin permeation
studies in Franz diffusion cells were carried out and at regular
intervals, 300 mL aliquots were taken and the DOX and DTX
concentrations were observed using uorescence spectrometry
and HPLC respectively. Fluorescence spectrometry showed that
67.8% of DOX permeated the skin within 48 hours aer DOX-
MN application, whereas a high release of 73.1% was
observed for DOX–DTX-MNs. Tape stripping was used to
measure the amount of drug within the stratum corneum and it
was found that 3.6% was present for the DOX-MNs. To measure
the amount of DOX within the epidermis, the skin sample was
homogenised, and drug was extracted showing that 21.9% of
DOX was present for DOX-MNs. Similar results were seen for the
DOX–DTX-MNs. Both the release and skin permeation studies
showed that DOX was released from the various DMNs faster
than DTX, which was studied by HPLC and is described later.
Fourier transform infrared (FTIR). In FTIR, an infrared (IR)
beam is used to illuminate a sample. Some of the IR is absorbedThis journal is © The Royal Society of Chemistry 2021and some is transmitted at various wavelengths. The IR that
reaches the detector is therefore different to the beam that
illuminated the sample and those differences in IR can be used
to form a spectrum that represents the sample and its func-
tional groups. FTIR spectra are known as ngerprint spectra
because different functional groups have different wavelengths;
therefore each sample will have its own unique spectrum.124
Bhatnagar et al.105 also used FTIR to characterise their DMNs.
They analysed plain DOX and DTX drugs and PVA and PVP
polymer solutions as well as drug loaded DMNs themselves.
They observed major peaks for PVP at 1630.56 cm1 and
1266 cm1 representing the C]O and C–N groups respectively.
DOX has characteristic bands at 3222 cm1 (N–H amine),
2884 cm1 (C–H), 1725 cm1 (C]O) and 1277 cm1 (C–O),
whereas DTX has characteristic bands at 3420 cm1 (N–H),
1685 cm1 (ester group) and 700 cm1 (N–H). Although the
characteristic peaks can be seen for each drug alone in polymer
solution or the DMNs, when combined, these characteristic
peaks cannot be seen.
X-ray diffraction (XRD). When an X-ray beam illuminates
a sample, the beam is either scattered or absorbed.125 In XRD,
the scattered X-rays cause interference which is measured and
can produce a spectrum. In an XRD instrument, the X-rays are
generated in a cathode tube, producing electrons which are
accelerated towards the sample by applying a voltage. If the
electrons have sufficient energy, they can dislodge the electrons
in the inner shell of the sample, producing a characteristic X-ray
spectrum. Each element has its own unique set of components
which allow for the identication of elements within the
sample.126
DMNs can be characterised by XRD, as well as analysing how
storage affects the polymer matrix. Kolluru et al.120 investigated
the use of a DMN patch, consisting of 35% w/v% sh gelatin
and 10% w/v% D-sorbitol, for the vaccination of polio. XRD was
used to analyse the changes in the matrix structure of the
DMNs. The measurements were made in a q–2qmode with a Cu
Ka source at 45 kV and 40 mA. Chips of the DMNmatrix showed
a peak at 20, which suggests that the matrix is amorphous due
to the DMNs being mainly composed of gelatin from the poly-
mer matrix and maltodextrin which the antigen was constituted
into. Freshly made DMNs also showed the presence of a peak at
around 42, which suggests that a crystalline phase was also
present due to D-Sorbitol. However, over storage time, this
crystalline peak decreased in height suggesting that the DMNs
becamemore amorphous over time as residual water evaporates
further.
A similar system, a Cu Ka source at 45 kV and 40 mA, was
used to study DOX and DTX loaded DMNs and analysis showed
peaks present for the drugs and matrices used in fabrication in
all samples.105 Another way to use XRD is to characterise NPs
before encapsulating them into DMNs, like Yan et al.127
Nanoindentation. A nanoindenter is a depth-sensing
indenter that constantly monitors its load and position rela-
tive to the surface of a sample during indentation. They can be
used to measure a wide range of properties, such as hardness,
elastic modulus, fracture toughness, etc.128 The ability of
strengthening CMC-MNs by incorporating layered doubleAnal. Methods, 2021, 13, 3326–3347 | 3335































































































View Article Onlinehydroxide (LDH) NPs into the matrix has also been investi-
gated.127 The indenter pressed the DMNs 2000 nm deep into
materials. The DMNs were then observed by SEM at a 45 tilt.
They observed an increase in load required to penetrate to the
same depth as they increased the LDH-NP concentration within
the CMC-MNs. This suggested that the encapsulation of LDH
into CMC-MNs signicantly increases their mechanical
strength in comparison to plain CMC-MNs. The hardness and
elastic modulus of the CMC-MNs were also observed as the
LDH-NP concentration was increased, showing that the hard-
ness increased as expected; however the elastic modulus rst
increased up to a concentration of 5 wt% LDH-NPs, and then
decreased again by 10 wt%. It was concluded that adding LDH-
NPs can signicantly enhance the indentation resistance,
making CMC–LDH-MNs much stronger than pure CMC-MNs.Imaging
Light microscopy. There are many forms of light microscopy
other than conventional microscopy, such as brighteld
microscopy, darkeld microscopy, uorescence microscopy,
confocal microscopy, etc. Light microscopy uses visible light as
the source. Light microscopy was used by Littauer et al.93 to
conrm the integrity and uniformity of needle geometries
themselves. The DMN matrices consisted of PVA and either
BSA, TRD or CMC encapsulating granulocyte-macrophage
colony stimulating factor (GM-CSF). Bioavailability studies
performed by light microscopy showed that the GM-CSF
released from the DMNs caused changes in bone marrow,
suggesting that the drug retained its activity even aer being
formulated into the DMN matrix. Light microscopy has been
used for other analyses, not just drug release studies,103 such as
characterisation106,119 and dissolution studies of DMNs.109 More
ways in which the specic types of light microscopy have been
used are detailed below.
Brighteld microscopy. In brighteld microscopy, the
sample itself is dark and the background is bright, as the
sample is illuminated from beneath, contrasting the image. The
sample is placed on the stage and incandescent light is focused
by an aperture onto a condenser lens beneath the specimen,
making sure that light is coming in from all angles. The light
then passes through the sample and is magnied by the
objective lens, transmitting it to the eyepiece. Parts of the
sample absorb light and others scatter it, allowing the sample to
be seen as it is contrasted.129 Brighteld microscopy has been
used in many ways, including for the characterisation102,130 and
dissolution studies97,131 of DMNs.
CMC–TRD dissolvable MN arrays were studied as potential
transdermal DDSs for human growth hormone (hGH).132 The
arrays consisted of needles of height 600 mm, base diameter 300
mm and tip diameter 10 mm. These arrays were imaged using
brighteld microscopy and showed a fully formed array, with
sharp tipped needles. In vivo studies were carried out in hairless
rats by ve different administration methods – placebo of CMC
only; hGH only; hGH solution mixed with CMC; hGH-MNs;
hGH-MNs aer 3 months of storage – and plasma hGH
concentration was monitored. It was observed that the hGH3336 | Anal. Methods, 2021, 13, 3326–3347concentration initially rapidly increased within the rst hour
and then sharply decreased over the next 6 hours. This trend
was seen for all ve methods; however the absolute concentra-
tions and bioavailability differed. Aer euthanasia, brighteld
microscopy was used to study the skin reactions of the mice.
The skin was biopsied and histologically sectioned into 1 mm
thick pieces. They were then stained with hematoxylin and
eosin before viewing. The DMN arrays of CMC and CMC–TRD
showed slight erythema of the skin, whereas subcutaneous
injections showed no erythema. However, all skin reactions
seen were not severe enough to cause safety or cosmetic
concern.132 This study shows the different ways in which
brighteldmicroscopy can be used to image arrays or the effects
of arrays on tissue.
Darkeld microscopy. Darkeld microscopy is similar to
brighteld microscopy in that the sample is illuminated from
beneath. However, in brighteld, the sample is illuminated
from all angles, so both scattered and unscattered light is
detected. Meanwhile, in darkeld, the inverted hollow cone of
illumination is directed by a reection mirror and light-
shielding plate towards the specimen at high angles of inci-
dence, meaning that undeected light cannot reach the objec-
tive. Therefore, only scattered light is detected, and the
background appears dark.133
Earlier we briey discussed how Bhatnagar et al.105 encap-
sulated anti-cancer drugs into DMNs. As DOX is uorescent, it is
visible under darkeld microscopy. The pyramidal shape of the
needles can be seen distinctly, and the sharp needle tips are
identiable. The uorescence appears uniformly spread
through the needle tips and backing plate, suggesting the
uniform distribution of DOX within the DMN matrix.
Dissection microscopy. Dissection microscopy, also referred
to as stereomicroscopy, is another form of light microscopy,
which typically uses reected, not transmitted, light to examine
dissected biological samples. Due to its longer working
distance, it has lower magnication than other forms of light
microscopy.134 Many studies use dissection microscopy to
image DMNs for many different characterisation methods
including imaging before and aer compression tests to
observe fracture force;99,101 to analyse the shape and dimensions
of the MN itself;105 and to analyse the surface morphology of the
DMNs.109
An example study that used stereomicroscopy to image both
skin aer DMN insertion, aer histology to determine the
penetration depth and aer drug delivery, was carried out by
Sullivan et al.135 They treated porcine skin with the fabricated
PVP-MNs, in a 10  10 array, and then stained the skin post-
insertion so the sites of insertion could be identied when the
skin surface was imaged. The microscopy images showed that
100 needles entered the skin and when the array was imaged
aer, no needles were broken or deformed, suggesting that
their PVP-MNs had enough mechanical strength to withstand
insertion into skin. The PVP-MNs were loaded with b-galacto-
sidase, which is enzymatically active and when stained with X-
gal, gives a blue colour. Porcine skin was treated with PVP-
MNs containing b-galactosidase and when histologically
sectioned and imaged, a blue dye was seen, showing that notThis journal is © The Royal Society of Chemistry 2021































































































View Article Onlineonly do the PVP-MNs successfully deliver b-galactosidase, but
they also do not alter the enzymatic activity of this drug in the
process. Mazzarra et al.136 also visualised the application site of
their DMNs using stereomicroscopy by loading their DMNs with
a dye and allowing them to dissolve into the skin, releasing the
dye. The samples were then histologically sectioned into 50 mm
thick sections before being imaged.
Zoom microscopy. Zoom microscopy is another function
available on most light microscopes, where a continuous zoom
viewing can occur. Kim et al.137 used this feature to observe the
process of their DMNs being formed by droplet-born air
blowing. The DMNs consisted of 600 mmhigh needles of various
layers, which were labelled and visible during zoommicroscopy.
The layers consisted of CMC, hyaluronic acid (HA) and PVP.
Fluorescence microscopy. A sample containing uorophores
is illuminated with light of a specic wavelength, which is
absorbed by the uorophores, causing them to emit light of
longer wavelengths. The illumination light is separated from
the surrounding uorescence by a spectral emission lter. The
lters and the dichroic beamsplitter match the spectral excita-
tion and emission characteristics of the uorophore used to
label the sample. A single uorophore is therefore imaged at
a time, so if several uorophores are present, they are imaged
separately and then combined to form a multicoloured
image.138
Xu et al.109 used uorescence microscopy when fabricating
CAM-NPs encapsulated into PVP-MNs for wound healing. They
imaged their 15 15 arrays to observe whether the needles were
fully formed and how well distributed the NPs were within the
DMN matrix. The images showed nice sharp needles of pyra-
midal shape with uorescence present only in the needle tips.
To determine whether their PVP-MNs containing CAM-NPs were
capable of overcoming the barrier of biolms on wounds, they
used sulforhodamine B as a model drug within the DMNs and
imaged the biolms aer the application of the array. The
images showed the disruption of the biolms aer PVP-MN
application and some dye had diffused into the biolm
matrix, suggesting that CAM-NPs would be successfully deliv-
ered to wounds through the biolms if administered by DMNs.
These images were compared to the images of topically applied
sulforhodamine B solution, which showed no biolm disrup-
tion, further supporting this conclusion.109
Wang et al.130 used uorescence microscopy to observe the
cellular expression of cells treated with up-conversion nano-
particles (UCNPs), with or without encapsulation into HA-MNs.
The cells were stained with a nuclear stain before imaging to
show successful delivery and gene expression.
Another way to use uorescence microscopy is to measure
the drug loading of DMNs, whether using a dye as a model
drug139,140 or a uorescent drug itself.102 It can also be used to
observe the penetration of DMNs and drug release to the skin
surface, as well as aer histology to observe uorescent drug
molecules as deep as the dermis.102
Confocal microscopy. In confocal microscopy, coherent light
is emitted by a source and focused onto a single point. The
pinhole physically blocks light emitted from a region away from
the focal plane. Therefore, only light from the in-focus planeThis journal is © The Royal Society of Chemistry 2021passes through to the detector. Reected uorescence from the
sample passes back through the mirror and pinhole onto the
detector.141 The sample is scanned across in a focal plane in two
dimensions to generate an image.
There are various types of confocal microscopy, for example
confocal laser scanning microscopy (CLSM). This type of
confocal microscopy allows optical sectioning and depth
selectivity of the sample. In CLSM, the light source is a laser
which passes through an aperture and is focused by the objec-
tive lens before reaching the sample. Emitted photons are
collected and the image is built up pixel-by-pixel.142 CLSM has
been used widely for the analysis of DMNs including charac-
terisation,105 dissolution studies99,101,140 and cell internalisation
of drug molecules from DMNs.130
Another type is reectance confocal microscopy (RCM)
which uses a diode laser, giving off monochromatic and
coherent light, which passes through a beam splitter and then
an optical lens and onto the skin. The light penetrates the skin,
illuminating an area of tissue, and any light reected from this
point passes back through the lens and is focused by a pinhole
into the photodetector.143
The ability of strengthening CMC-MNs by incorporating
LDH-NPs into the matrix was discussed briey earlier.127 They
used both types of confocal microscopy described above to
observe the penetration and drug delivery of CMC-MNs. Fluo-
rescein isothiocyanate (FITC)–dextran, which was used as
a model drug, was mixed with a solution of CMC with LDH-NPs.
RCMwas used to image the porcine and human skin, which had
been treated with DMNs, at an excitation wavelength of 785 nm.
Uniform penetration of the stratum corneum was observed for
insertion into porcine skin with LDH-NP loaded CMC-MNs, to
a depth of 71 mm. However, insertion by CMC-MNs without
LDH-NPs did not show uniform insertion, as only central nee-
dles penetrated the skin to a depth of 46 mm. This trend was also
seen in human skin, showing a penetration depth of 64 mm and
39 mm for CMC-MNs with and without LDH-NPs respectively.
These data suggest that LDH-NPs strengthen the CMC-MNs.
The same samples were then imaged by CLSM to observe
where the model drug had been released. For this the tissue was
stained with a nuclei stain and then excited at both 405 nm and
488 nm to visualise the stain and FITC–dextran respectively. The
payload was seen to have been delivered vertically and some had
even diffused within the skin aer only ve minutes. RCM was
also used to image the DMNs aer certain time periods pene-
trating into skin. It was seen that almost all of the DMNs had
dissolved aer only one minute in the skin. These results show
the potential of using various types of confocal microscopy for
the imaging of not only the skin, but also the DMNs themselves.
Confocal Raman spectroscopy. This involves coupling
a Raman spectrometer with a confocal microscope to improve
resolution and depth proling.144 It is used to evaluate the
bioavailability of drugs by examining the skin using a Raman
spectrometer. Caspers et al.145 used a 720 nm near-IR laser light
at a distance from the skin to image the tissue. They success-
fully determined the water concentration of volunteers' skin
which demonstrates the potential of imaging skin in vivo to
observe the hydration. It could also be used for investigating theAnal. Methods, 2021, 13, 3326–3347 | 3337































































































View Article Onlinebioavailability of drugs by determining their concentration in
the skin. The coupling of Raman spectroscopy with confocal
microscopy adds the element of quantitative measurements,
not just qualitative.
Scanning electron microscopy. In SEM, a beam is scanned,
in a raster-scan pattern, over the surface of a sample causing
electrons to interact with atoms in the sample and produce
various signals. These signals contain information about the
surface topography and composition of the sample. The posi-
tion of the beam is combined with the intensity of the detected
signal to produce an image. In the most common SEM mode,
secondary electrons emitted by atoms excited by the electron
beam are detected using a secondary electron detector. The
number of secondary electrons that can be detected, and thus
the signal intensity, depends, among other things, on specimen
topography. Various types of signals are produced including
secondary electrons, reected or back-scattered electrons,
characteristic X-rays and many more. An electron beam is
emitted from an electron gun and is focused by one or two
condenser lenses. When the primary electron beam interacts
with the sample, the electrons lose energy. The beam current
absorbed by the specimen can be detected and used to create
images.
UCNPs were fabricated into HA-MNs and their morphology
was studied using SEM.130 The HA-MNs were studied both in the
presence and absence of UCNPs, showing pyramidal 10  10
arrays in both cases. The height of the needles was found to be
1000 mm and the morphology did not change when UCNPs were
encapsulated.
Other studies have used SEM for the characterisation of
DMNs, mainly in terms of shape and morphology,109,127 and
some require various ways to make their DMNs visible, i.e.
sputter coating with gold.119
Computerised tomography (CT). CT is the computerised X-
ray imaging of a sample where the X-ray beams, aimed at the
sample from various angles, produce signals, which form
a cross-sectional image using a computer processer.146 Abram-
son et al.147 used a luminal unfolding MN injector (LUMI) device
to deploy DMNs within the small intestine so that they can
release insulin and lower blood glucose levels. MicroCT was
used to image the DMNs ex vivo, showing tissue penetration up
to 800 mm without perforation.
Although Abramson demonstrated the ability to use CT to
image DMNs in situ, Loizidou et al.87 demonstrated imaging
DMN arrays themselves, as well as in vitro on porcine skin. The
CT scanner used had an adjustable voltage between 20 and 50
kV and a current up to 800 mA. They compared different
geometry DMNs and their penetration depth by CT scan,
observing that square and triangular DMNs had greater pene-
tration than hexagonal DMNs. The process of CT scan imaging
can be non-invasive when imaging tissue; however when
imaging the DMN arrays themselves, they may need to be
coated.
Optical coherence tomography (OCT). OCT is a form of low
coherence interferometry that is non-invasive, producing real-
time cross-section images of a sample.148 These images are of
high axial resolution, between 1 and 15 mm, and it has also been3338 | Anal. Methods, 2021, 13, 3326–3347shown that OCT can reach penetration depths of 2–3 mm.149
The sample is either scanned laterally (ying spot OCT) or all
lateral pixels in the area of interest are ood illuminated (full
eld OCT) and proles of reectivity in depth are obtained for
each lateral pixel.150
This technique was widely developed for ophthalmology and
steadily penetrated other medical imaging elds as well as
being extended to non-destructive testing. There are already
several non-destructive testing reports of using OCT to image
microneedles.
Thakur et al.101 employed a swept-source Fourier domain
system at a wavelength of around 1305 nm, scan width of 2 mm,
scan rate of 15 B-scans per second and resolutions of 7.5 mm
laterally and 10 mm vertically to image fabricated PVP-MNs in
skin. They used these images to determine the penetration
depth of DMNs in ocular tissue. Lee et al.151 used a similar
wavelength system, however at an A-scan rate of 100 kHz and
power 30 mW, to visualise PVA–PVP-MNs that they had fabri-
cated. The visualisation of Gantrez DMNs, with photosensitiser
NPs encapsulated, in human volunteers was accomplished by
Donnelly et al.139 and the penetration of DMNs was measured to
be at a depth of 460 mm. However, no information on the system
used was given in the paper.
Over the past three years, several research groups reported
OCT systems applied to visualise the dissolution of DMNs and
the release of cargo from them. Chen et al.152 fabricated gelatin/
CMC patches containing R6G dye and imaged the dissolution of
the dye. A year later a LUMI device that deposits DMNs into the
small intestines to release insulin was fabricated.147 The DMNs
were imaged in situ at a wavelength of 1.3 mm once deposited by
the device and their dissolution was observed. Another study
used OCT to compare hydrogel-forming MNs and DMNs in
terms of the penetration depths and dissolution of OVA.153 The
potential of using OCT to track contrast agents released from
HA-MNs was demonstrated by Wang et al.130 These contrast
agents were made from UCNPs with siRNA encapsulated.
Although OCT has been used to image DMNs themselves or
in vitro in tissue samples, few have used OCT to image DMNs in
situ. Quinn et al.154 used a handheld topical OCT system to
image DMNs whilst inserted into human participant arms. This
system consisted of a swept-source at 1305 nm which imaged to
approximately 2 mm depth in skin with 7.5 mm lateral and 10
mm axial resolution. The 11  11 MN matrix was composed of
Gantrez and polyethylene glycol (PEG), with conical needles of
height 600 mm. This study154 evaluated the human variability in
applying DMNs to skin, where the insertion depths for each age
group were calculated and compared between self-application
and researcher application. For 20–30 year olds, no signicant
difference in insertion depths was seen. However, in the over
65 s group, the insertion depth from researcher application was
signicantly lower than that of self-application, which may be
due to researchers being wary of the age of the participants and
therefore being soer on application. There were no signicant
differences seen in the pore widths between the self-
administration by both age groups and of all ages, and all
applications. This study is an example of how OCT can be usedThis journal is © The Royal Society of Chemistry 2021































































































View Article Onlinefor characterisation101,130 in terms of penetration depth of
DMNs.
The above ndings demonstrate that OCT can be a useful
tool for both the characterisation of DMNs and the real time
monitoring of their application. However, for OCT to expand as
an imaging technique within the eld of microneedles,
a uniform evaluation of the OCT parameters is essential for
DMN characterisation and calibration of these parameters is
required. For example, OCT parameters for ophthalmology were
calibrated by the National Institute for Health Research in the
UK and National Institutes of Health in the US. The parameter
calibrations should include wavelength, power, and resolution,
as well as how these parameters affect DMNs.
Multimodal techniques. In terms of optical modalities, it is
recognised that investigation is only supercial due to scat-
tering and absorption and that the resolution decreases as the
depth of investigation increases. Therefore, in the last decade,
multiple reports have been published on the combination of
optical modalities155 in order to improve the specicity and
sensitivity of the investigation using a single modality. Different
modalities allow bringing together different categories of
information, such as the structure and function. For imaging
the eye, where OCT is mostly applied to, the combination of
OCT with confocal microscopy led to OCT and scanning laser
ophthalmoscopy (SLO) systems,156 termed OCT/SLO. Such
a combination allows pixel to pixel correspondence in the two
channels, where one of them can be used to guide the other one
and to minimise movement effects. The confocal (SLO) also
allows the addition of uorescence obtaining treble quanti-
cation, OCT & SLO & angiography.157 Triple channel function-
ality OCT, giving aggregated images similar to confocal
microscopy and uorescence, was also extended to robotic
scanners158 and embryo imaging.159
A system that combines bioluminescence and uorescence
imaging in 3D, providing tomographic images of internal
structures, has recently been produced.160,161 Termed an In Vivo
Imaging System (IVIS), this can also allow non-invasive imaging
of living organisms in real time. This technique is a relatively
new development and was used by McCaffrey et al.162 to image
mice that had been administered DNA loaded NPs in PVP-MNs.
These DMNs were applied to both ears of mice and imaged for
bioluminescence 24 and 48 hours aer administration. Unfor-
tunately, the mice did not show any bioluminescence; however
luciferase production was seen in the livers and kidneys at both
time points. Another study observed the delivery of molecular
beacons by UCNPs encapsulated into DMNs using the uores-
cence imaging feature on the IVIS.130
A system similar to this has been used by Dadkhah et al.163 to
image tissue. It combines OCT, photoacoustic (PA) microscopy,
optical doppler tomography and confocal uorescence micros-
copy to give functional, molecular and structural informa-
tion.155 While an OCT signal is created by scattering (leading to
morphology characterisation), the PA signal is created by
absorption (leading to functionality characterisation). Advances
in technology, using the same optical source for both OCT and
PA, allows an easier integration of OCT with PA.164This journal is © The Royal Society of Chemistry 2021Goswami et al.165 used an OCT/SLO system to image nano-
particles in mice retina. They used an SLO system with a wave-
length of 488 nm as the light source and a wavelength of 685 nm
to photoactivate the NPs. The OCT system used had a band-
width of 132 nm, wavelength of 860 nm and power of 600 mW.
This study shows the possibility of using multimodality systems
to image NPs in vivo once they have been delivered by the DMNs.
Osseiran et al.166 used a system that combined corneometry,
which is used to measure the hydration of supercial layers of
the skin, and coherent Raman scattering (CRS) to study the
structure and function of the stratum corneum of human skin.
The CRS consisted of a dual-output laser source, with one
output being tuneable from 680–1300 nm and the other being
kept constant at 1040 nm. The combined system was used to
observe how topically applied compounds act on skin and
measure their uptake.
These studies demonstrate the potential of multimodality
systems as imaging techniques, with the combinations oen
leading to quantitative analysis as well as qualitative analysis.Drug release and activity
Plate readers. Plate readers can be used to quantify the
presence of uorescence and absorption in a sample by con-
verting the analytes present in the samples into optical signals.
They could be used for both characterisation, e.g. the intensity
of drug cargo in a dissolved DMN, or drug release, e.g. by using
intensity readings from the release medium to calculate the
concentration of the drug present, among other techniques.
The samples need to have chromophores or uorophores
present; therefore if the drug cargo does not have these prop-
erties, it may need to be doped or replaced with a dye model
drug to be observed.
Choi et al.167 demonstrated the potential of using DMNs,
fabricated from CMC–TRD for the needles and SUC–PVA for the
backing plate, as DDSs for vaccination with HBV. They used
ELISPOT analysis at 450 nm to observe T-cell responses, by
administering HBV either by intramuscular (IM) injection or
DMNs. A higher T-cell response was seen for DMN vaccination
compared to IM vaccination immediately aer administration
and from ve weeks post-booster vaccination. This demon-
strates another way that plate readers can be used for studying
drug activity.
Plate readers have mainly been used to analyse assays, such
as the CCK-8 assay used to determine the cytotoxicity of mate-
rials to broblast cells. The cytotoxicity of CAM-NPs was
observed at 450 nm and a viable cell number was determined.109
The ELISA assay is used to quantify peptides, proteins, anti-
bodies and hormones. Edens et al.97 used the ELISA assay to
detect the poliovirus antibodies at 450 nm.
They can also be used to determine drug concentration, for
example the concentration of FITC–dextran from the release
medium at an excitation of 493 nm and an emission of
520 nm.101 Plate readers can also be used during character-
isation to determine the concentrations of drugs within DMNs.
Ultraviolet-visible (UV-Vis) spectroscopy. UV-Vis spectros-
copy measures the intensity of light that is transmitted throughAnal. Methods, 2021, 13, 3326–3347 | 3339































































































View Article Onlinea sample with respect to a reference or blank sample. This
allows the absorption to be calculated by using the Beer
Lambert law. When the light passes through the sample, it
excites electrons in the sample, causing the promotion of the
electron to a higher orbital. This promotion of an electron
causes energy to be used and therefore absorption occurs.168
Aditya et al.169 used UV-Vis spectroscopy to observe the
dissolution of collagen–PVP-MNs doped with trypan blue,
a model drug. The DMNs were dissolved in deionised (DI) water
or 0.8% NaCl and UV-Vis was used to measure the dye release
every 20 seconds. The DMNs readily dissolved, releasing trypan
blue into the medium, in both DI and NaCl. However, it was
found to be faster in DI water than in NaCl. They also observed
a relationship between the height of the needle and the loading
capacity where the longer the needle, the more dye it could
encapsulate.
UV-Vis spectroscopy was also used to study the stability of b-
galactosidase encapsulated into sugar glass at an absorbance of
405 nm. The study showed that although the enzyme lost
activity over storage time, this loss was signicantly reduced by
storage in sugar glass.119
Attenuated total reectance-Fourier transform infrared
(ATR-FTIR). ATR-FTIR is a method to quantitatively determine
the amount of drug in tape strips or the stratum corneum.37 An IR
beam is directed at a crystal which creates an evanescent wave
that extends beyond the surface of the crystal into the sample,
which is held in contact with the crystal. The beam then returns
to the crystal and is directed to the IR detector which records the
beam as an interferogram.170
Kochhar et al.171 fabricated DMNs from a poly(ethylene
glycol)diacrylate (PEGDA) matrix encapsulating lidocaine. In
vitro drug release studies showed that the amounts of lidocaine
released were lower than that encapsulated. Therefore, they
used ATR-FTIR to observe whether there are any interactions
between the PEGDA matrix and lidocaine.172 They fabricated
PEGDA with lidocaine lms and compared it to the PEGDA
solution with and without lidocaine, and found that the N–H
peak seen in pure lidocaine in pre-polymer solution shied and
broadened in the PEGDA lm spectrum. They concluded from
these results and comparison to Cui et al.'s173 results that the
lidocaine is possibly hydrogen bonded with the PEGDA matrix,
preventing drug release.172 The disappearance of the C]C
peaks in the polymerised PEGDA lm, compared to liquid
PEGDA, conrmed the cross-linking and polymerisation of
PEGDA in the lms.
Mass spectrometry (MS). MS is used to identify the mass of
atoms or molecules in a sample, allowing the identication of
the sample. An ion source bombards the sample with electrons
causing positive ions to be formed in the gas phase. These ions
are then accelerated through the mass analyser and are
deected by the magnetic eld according to their mass-to-
charge (m/z) ratio. Lighter ions are deected more than
heavier ones, yet some heavier ones are not deected enough
and therefore they do not reach the detector. The ions detected
are then displayed as a spectra of signal intensity to m/z.174
There are many different types of MS, including tandem MS,
liquid chromatography (LC)/MS, ultraperformance MS,3340 | Anal. Methods, 2021, 13, 3326–3347accelerator MS, etc. The studies described below show how
different types of MS can be used for the analysis of drug release
studies both in vivo or in vitro.
Chen et al.116 used tandemMS, at a ow rate of 0.3 mLmin1,
to analyse the plasma concentration of mice as part of their in
vivo studies on whether GO-doping of DMNs is practical for
transdermal drug delivery. Mice with melanoma tumours were
administered an anti-melanoma drug HA15 by three different
methods – GO–HA15-MNs; HA15-MNs; subcutaneous injection
of HA15. They were also compared to two controls of saline
DMNs and GO-MNs. Immediately aer every treatment, all mice
were irradiated with a near-IR laser for 10 minutes, no matter
what group they were in. The saline MNs and GO-MNs showed
no tumour growth inhibition. One and three hours aer the
administration, both GO–HA15-MN and HA15-MN mice
showed signicantly lower plasma HA15 concentrations than
the mice that were subcutaneously injected. However, aer 12
hours, this had drastically changed and the two drug DMNmice
groups now had signicantly higher plasma HA15 concentra-
tions than the injection group. Although both drug DMN groups
showed a plasma concentration prole of stable concentration
followed by a slow decrease, the GO–HA15-MN mice plasma
concentrations were higher than those of the HA15-MN mice at
all time points.
LC/MS was used to quantify the concentration of dihydro-
ergotamine mesylate (DHE) loaded into PVP-MNs. Tas et al.103
used LC/MS, at 25 C and a ow rate of 0.5 mL min1, to form
a calibration curve of known DHE concentrations before
running blood plasma from in vivo bioavailability studies to
determine the amount of DHE in the mouse plasma. The mice
were administered DHE by one of the three different methods –
IV injection of DHE; subcutaneous injection of DHE and PVP-
MNs loaded with DHE. The absolute and relative bioavail-
ability of DHE administered via PVP-MNs was 72% and 97%
respectively, which shows that DMNs have great potential to be
used as transdermal DDSs instead of injections.
Ultraperformance MS was used by Li et al.106 to determine
the concentration of LNG that is released from effervescent
DMNs in vitro as an alternative form of contraception. The MS
column was maintained at 50 C and at a ow rate of 0.3
mL min1. The DMNs were dissolved in PBS containing Tween
80 and varying concentrations of ethanol (0–25%) at 37 C
whilst being shaken. Aliquots of the release medium were
collected at different time points and analysed by ultra-
performance MS. There was no burst release observed, just
a sustained release of 1.4% per day over at least 60 days. The
presence of ethanol increased the burst release up to 25% on
day 1 at a maximum ethanol concentration of 25%. No matter
whether ethanol was present or not, or in what concentration,
all studies showed that LNG was released over one month in all
samples, which was the desired time frame.
Gel permeation chromatography (GPC). GPC is a form of
chromatography where the stationary phase is solid, and the
mobile phase is liquid. The sample is separated by molecule or
polymer size. The mobile phase is pushed through the
stationary phase column with a pump and an injection port
introduces the sample onto the column. The sample becomesThis journal is © The Royal Society of Chemistry 2021































































































View Article Onlineseparated by size and ows out of the column to the detector –
larger polymers in the sample ow faster than smaller poly-
mers, which get trapped in the pores of the column.175
Mazzara et al.136 loadedmicroparticles (MPs) containing OVA
into DMNs and showed successful delivery of their cargo of OVA
and other drugs to their targets through a sustained release.
They used GPC to determine the mass of MPs that dissolved
from the PVA–SUC-MNs by analysing the mass of MPs le in the
patch aer insertion into dorsal mouse skin in vivo for 20
minutes. The analysis showed that only 25% of the MPs in the
array were delivered. GPC could also be used in a similar way for
the characterisation of DMNs by quantifying the mass of drug
NPs inside the whole DMN before use or for other drug release
studies, such as Franz diffusion cell studies, by taking aliquots
at regular intervals and measuring the mass of drug NPs
present.
High performance liquid chromatography. HPLC, like GPC,
uses a solid stationary phase and liquid mobile phase. There are
many types of HPLC which determine the way in which the
sample is separated. Normal-phase and reverse-phase HPLC
both separate analytes by polarity; however, in normal-phase,
the mobile phase is non-polar, whereas in reverse-phase it is
polar, and the stationary phase is hydrophobic. Therefore,
normal-phase separates analytes by their polarity whereas
reverse-phase separates analytes by their dispersive forces.
Another form of HPLC is ion-exchange, where analytes are
separated by ionic forces. The fourth type of HPLC is size-
exclusion, where analytes are separated, like the name
suggests, by their size.176 HPLC can be used for the character-
isation of DMNs105 as well as drug release studies.109
HPLC can be used in many ways to determine the concen-
tration of a drug. Tas et al.103 used HPLC coupled with a uo-
rescence detector to determine DHE concentration, both during
the characterisation of their PVP-MNs and drug release studies.
The reverse phase column was kept at 35 C and a ow rate of
1.2 mL min1 was set. The uorescence detector was set to an
excitation wavelength of 280 nm and emission wavelength of
350 nm. For the characterisation, the PVP-MNs were dissolved
in DI water at room temperature and analysed showing that
108% of the 50 mg DHE used in fabrication was present in the
dissolution medium. They concluded that this showed that
their fabrication process was successful for drug loading of
DMNs. Their ex vivo-studies on porcine skin involved inserting
the PVP-MNs for a period of time and at regular intervals,
removing the DMNs and tape stripping the skin to remove
residual DHE. The used PVP-MNs were dissolved in DI water
and analysed by HPLC to determine the concentration of DHE
le. The amount of drug delivered was found to increase over
time whilst the PVP-MNs stayed in the skin, with 62% released
aer one minute and up to 79% aer ten minutes. In vitro
studies were carried out by dissolving the PVP-MNs loaded with
DHE in DI water at 32 C and removing aliquots at regular time
intervals for analysis by HPLC. This study showed the desired
rapid dissolution of DHE within two minutes of dissolution.
HPLC was also used to assess DHE solubility with increasing
PVP concentration, and a proportional relationship was
observed.This journal is © The Royal Society of Chemistry 2021Bhatnagar et al.105 showed the ability to use HPLC to deter-
mine the concentrations of drug cargo in DMNs fabricated from
PVP and PVA. A calibration curve was plotted for known
concentrations of DTX and then drug released from DMNs
dissolved in PBS was determined. For these studies, the column
was maintained at 25 C with a ow rate of 1 mL min1. The
detector was set to an absorbance wavelength of 230 nm. The
concentration of DTX loaded into the DMNs was 302.4 mg in
DTX-MNs and 227.0 mg in DOX–DTX-MNs. The release proles
showed that only 90% of DTX was released within 15 minutes
from both types of DMNs. Ex vivo skin permeation studies
showed that only 33.6% and 26.7% of DTX from DTX-MNs and
DOX–DTX-MNs respectively had permeated mouse skin within
48 hours. A lag in permeation was observed for DTX from DOX–
DTX-MNs also.
Circular dichroism (CD). CD is the absorption difference
between le and right polarised light. In a circular dichroism
spectrometer, right and le polarized light is alternated. If the
sample exhibits CD, the light intensity will uctuate when it
passes through the sample. Any unabsorbed photons from the
light hit a photomultiplier tube, producing a current. This
current is detected by an amplier, producing a current that has
a DC component that depends on the light absorption and an
AC component that depends on the CD.177 This technique can
be used for monitoring the stability of drug cargo throughout
the fabrication process.137 For example, monitoring insulin
stability aer the fabrication of DMNs via droplet-born air
blowing (DAB) and then aer a further four weeks of storage, by
carrying out CD spectroscopy between 245 and 200 nm at
a bandwidth of 2 nm and scan rate of 100 nm min1. No
signicant change was seen in the stability of insulin aer this
fabrication method or storage.
As discussed earlier, Lee et al.131 studied the effect of the
geometry and DMNmatrix on mechanical strength, penetration
and drug release. To measure protein stability, CD was carried
out on untreated lysosomes, lysosomes from CMC-MNs one
hour aer fabrication and lysosomes from CMC-MNs two
months aer storage. There was no change of the lysosome
secondary structure detected for all. However, although there
was no enzyme activity loss aer encapsulation into the CMC-
MNs, there was a slight loss aer two months of storage
giving only 96% enzyme activity. As demonstrated, CD can be
used to determine whether the activity of enzymes or proteins
encapsulated into DMNs directly or into NPs before being
encapsulated into DMNs is affected by the DMN matrices.
Flow cytometry. Flow cytometry measures the volume of cells
in a rapidly owing uid. A sample of cells in a single-cell
suspension is taken up into the instrument and surrounded
by a sheath uid.178 This uid takes the cells past the laser one
cell at a time, causing light to be scattered from the cells. This
scattered light is detected as forward and side scatter. The
uorescence detector measures the uorescence emitted from
the cells or particles.179 Flow cytometry can be used to monitor
the expression of cells aer exposure to drug cargo before and
aer incorporation into DMNs to see if the fabrication process
affects drug activity.108,162Anal. Methods, 2021, 13, 3326–3347 | 3341































































































View Article OnlineZaric et al.107 used ow cytometry to asses surface marker
expression triggered by OVA-NPs in poly(methyl vinyl ether)
(PMVE)/maleic acid (MA)-MNs. First, they analysed dendritic
cells that were treated with OVA-NPs and compared the results
to those of untreated cells to demonstrate cellular uptake.
Proliferation studies showed that the OVA-NPs were able to
induce antigen-specic proliferation, which shows that the
OVA-NPs are taken up and processed by dendritic cells, acti-
vating a T cell dose response. In vivo studies on mouse ears with
plain PMVE/MA-MNs or PMVE/MA-MNs with plain NPs encap-
sulated were performed by ow cytometry and a localised
inammatory response was seen, which could be what initiates
or enhances the immune response to vaccines delivered by
DMNs. To determine whether the plain PLGA-NPs or tetrame-
thylrhodamine (TRITC)-NPs were taken up by lymph nodes, the
ear proximal draining lymph nodes were analysed 72 hours
aer DMN application. The data showed that TRITC-NPs were
present in lymph nodes for dendritic cell-enriched suspensions;
however for blood-derived dendritic cells, no uptake of TRITC-
NPs was detected, suggesting that the drug cargo of DMNs
stays localised to the vaccination site. When immunised with
OVA-NPs in PMVE/MA-MNs, proliferation and an immune
response were observed. These mice were then tumour chal-
lenged and ow cytometry analysis demonstrated an efficient
antigen-specic response, as well as the presence of memory
cells, suggesting that OVA vaccination through DMNs has
potential. All ow cytometry was done using phycoerythrin
staining of cells or tissue.107
Closing remarks
The interest in nanomaterials and their delivery into the human
body in order to create a new generation of medicine is still
unabated now, more than 30 years since the invention of
scanning tunnelling microscopy (STM) and the subsequent
development of atomic force microscopy (AFM). These two
analytical tools caused the eld of nanotechnology to expand
and accelerate signicantly, starting with the discovery of
fullerenes and carbon nanotubes in the 1980s, leading to
carbon dots and a myriad of nano-engineered objects in the
early 2000s, many designed with the aim to specically target
cells or precise locations in the human body with minimum
collateral exposure to other cells or tissues. Hundreds of thou-
sands of articles were published, thousands of patents have
been led, and vast amounts of resources (nancial and non-
nancial) were invested, yet the childish question ‘Are we
there yet?’ still has one simple answer – ‘Not just yet’. The
introduction of microneedles, which can even be 3D printed
with very high resolution and accuracy, signals a new era for
nanomedicine. Since nanotechnology progressed rapidly aer
the discovery of specic analytical tools (STM and AFM), in this
review, we have provided a very comprehensive roadmap of
analytical methods used to characterise the unique properties
of nanomaterials and an exciting type of drug formulation –
dissolvable microneedles. We believe that the specic analytical
examples and the best laboratory practices mentioned in this
review will serve as a useful guide and inspiration to many3342 | Anal. Methods, 2021, 13, 3326–3347scientists working on next-generation drug delivery systems
intended to be used in oncology; for the mass administration of
vaccines; new therapeutic systems for inammation; microbial
infections; and to re-accelerate stem-cell research in tissue
repair, just to name a few. Importantly though, this review
might also offer useful information for researchers working in
seemingly unrelated disciplines, producing nanopesticides and
even reagents for biomedical diagnostics and testing.
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AbbreviationsAFM atomic force microscopy
ATR-
FTIRattenuated total reectance Fourier transform
infraredBSA bovine serum albumin
CAM chloramphenicol
CD circular dichroism
CLSM confocal laser scanning microscopy
CMC carboxymethyl cellulose
CRS coherent Raman scattering
CT computerised tomography
DDS drug delivery system
DHE dihydroergotamine mesylate
DI deionised
DLS dynamic light scattering
DMN dissolvable microneedle array
DOX doxorubicin
DSC differential scanning calorimetry
DTX docetaxel
FITC uorescein isothiocyanate
FTIR Fourier transform infrared
GM-CSF granulocyte-macrophage colony stimulating factor
GPC gel permeation chromatography
GO graphene oxide
HA hyaluronic acid
HBV hepatitis B vaccine
hGH human growth hormone
HPLC high performance liquid chromatography
IM intramuscular
IR infrared
IVIS in vivo imaging system
LC/MS liquid chromatography/mass spectrometry
LDH layered double hydroxide
LNG levonorgestrel








OCT optical coherence tomography
OVA ovalbuminThis journal is © The Royal Society of Chemistry 2021
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PMVE poly(methyl vinyl ether)
PVA polyvinyl acetate
PVP polyvinylpyrrolidone
RCM reectance confocal microscopy
S spike protein
SbD safe-by-design
SEM scanning electron microscopy
SLO scanning laser ophthalmoscopy
STM scanning tunnelling microscopy
SUC sucrose
TEM transmission electron microscopy
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